myMPNteam

That's a really thoughtful question, and it's great that you're researching your options carefully. While specific experiences from members with both an autoimmune condition and Besremi use aren't available here, there is some helpful general information about Besremi and JAK2-targeting treatments.

Besremi (ropeginterferon Show Full Answer

That's a really thoughtful question, and it's great that you're researching your options carefully. While specific experiences from members with both an autoimmune condition and Besremi use aren't available here, there is some helpful general information about Besremi and JAK2-targeting treatments.

Besremi (ropeginterferon alfa-2b) is an interferon therapy that works differently from Hydroxyurea (Hydrea). It is self-injected and has shown promise in treating PV by targeting the underlying JAK2 mutation more directly. One myMPNteam member shared that switching from Hydroxyurea to Besremi made a significant difference in how they felt and their overall quality of life. They noted it was too early to tell the full effect, but the change was meaningful for them.

It's worth noting that since you've now progressed to MF1, your treatment options may expand. JAK inhibitors like Ruxolitinib (Jakafi) are FDA-approved specifically for myelofibrosis, including post-PV myelofibrosis, and directly target the JAK2 pathway. Given your autoimmune history, this is especially important to discuss with your hematologist or MPN specialist, as interferon therapies can sometimes affect immune function. An MPN specialist at a major cancer center would be best positioned to weigh your allele burden, MF1 diagnosis, and autoimmune history together when recommending next steps.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Life With Polycythemia Vera: Ted’s Story

What Is a JAK2 Mutation?